Effect of in vitro aging on prostaglandin synthesis in cultured rat vascular smooth muscle cells. 1987

K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
2nd Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Cultured rat vascular smooth muscle cells from mesenteric artery produced prostaglandin (PG)E2, PGF2 alpha, PGI2 and thromboxane (TX)A2 in response to arachidonic acid, calcium ionophore A23187, vasopressin and angiotensin II. PGI2 was the major product among these PGs. PG synthesis in these cells decreased with in vitro aging, but the distribution pattern of PG synthesis did not change up to the passage level 56. Therefore, it is suggested that imbalance among PGs may not be directly implicated in vascular diseases in aging.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D014652 Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. Disease, Vascular,Diseases, Vascular,Vascular Disease

Related Publications

K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
September 1983, The American journal of physiology,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
April 1986, The American journal of physiology,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
September 1986, Prostaglandins,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
May 1994, The Journal of clinical investigation,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
November 1990, Biochemical and biophysical research communications,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
April 1987, The Journal of biological chemistry,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
May 2004, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
November 1980, Science (New York, N.Y.),
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
January 1988, Clinical and experimental hypertension. Part A, Theory and practice,
K Takeuchi, and K Abe, and M Sato, and M Yasujima, and T Hagino, and S Fang, and K Yoshinaga
February 1991, Biochimica et biophysica acta,
Copied contents to your clipboard!